- Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
- Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
- Avidity Biosciences to Participate in Upcoming Investor Conference
- Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Avidity Biosciences to Participate in Upcoming Investor Conferences
- Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
- Avidity Biosciences Honors Rare Disease Day®
- Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
- Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 29.29 |
---|---|
High | 30.54 |
Low | 28.40 |
Bid | 29.52 |
Offer | 29.53 |
Previous close | 28.91 |
Average volume | 928.91k |
---|---|
Shares outstanding | 95.62m |
Free float | 90.16m |
P/E (TTM) | -- |
Market cap | 2.76bn USD |
EPS (TTM) | -2.95 USD |
Data delayed at least 15 minutes, as of May 15 2024 20:59 BST.
More ▼